十六种中药方剂对糖尿病肾病心肾及生存获益的时间依赖性真实世界研究
该回顾性队列研究分析台湾2000-2017年健保数据,比较使用十六种具潜在肾保护作用中药方剂(PRCHMDKD)与匹配非使用者在整体及晚期糖尿病肾病患者中的心肾与生存结局。结果显示PRCHMDKD使用与终末期肾病、全因死亡及心血管死亡风险的时间依赖性降低相关,且未增加高钾血症风险。
要点
- PRCHMDKD使用与整体及晚期DKD患者ESRD、全因死亡和心血管死亡风险降低相关
- 限制平均生存时间分析显示PRCHMDKD组在ESRD、全因死亡和心血管死亡方面均有显著获益
- 使用至少四类或五类及多种PRCHMDKD方剂可提供增强的肾脏保护作用
核心结论
- 真实世界研究表明使用十六种PRCHMDKD可为DKD患者提供时间依赖性的心肾和生存获益,同时保证安全性。
研究设计与样本
- 回顾性队列研究,分析台湾2000-2017年全国健康保险理赔数据,采用Cox比例风险模型、限制平均生存时间、倾向评分匹配和竞争风险分析四种统计方法。
- 整体DKD患者队列纳入43,480名PRCHMDKD使用者和同等数量匹配的非使用者;晚期DKD队列纳入1,422名使用者和同等数量匹配的非使用者。
主要发现
- 整体DKD患者中,PRCHMDKD使用与ESRD调整风险比0.66(95% CI 0.61-0.70)、全因死亡0.48(0.47-0.49)、心血管死亡0.50(0.48-0.53)相关。
- 晚期DKD患者中,PRCHMDKD使用与ESRD调整风险比0.81(95% CI 0.65-0.99)、全因死亡0.59(0.50-0.70)、心血管死亡0.61(0.45-0.82)相关。
- 整体DKD患者中,PRCHMDKD组与非使用组的限制平均生存时间差异:ESRD为0.31年(95% CI 0.24-0.38),全因死亡为2.71年(2.60-2.82),心血管死亡为1.18年(1.09-1.28)。
- 晚期DKD患者中,PRCHMDKD组与非使用组的限制平均生存时间差异:ESRD为0.61年(95% CI 0.13-1.10),全因死亡为1.50年(1.03-1.98),心血管死亡为0.59年(0.22-0.95)。
- 高钾血症风险未增加,且多项敏感性分析结果一致。
关键数值与推荐
- 使用至少四类或五类及多种PRCHMDKD方剂与整体及晚期DKD患者增强的肾脏保护相关。
临床怎么用
- 在整体及晚期DKD患者中,可考虑使用十六种PRCHMDKD以降低ESRD、全因死亡和心血管死亡风险,并注意使用至少四类或五类方剂可能增强肾脏保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A causal connection between oxidative stress and inflammation in diabetes, along with its associated renal and cardiovascular complications, has been established. Sixteen prescribed potentially renoprotective Chinese herbal medicines for diabetic kidney disease (PRCHMDKD), which are scientific Chinese medicine (botanical drug) and categorized into five classes (clearing heat, nourishing yin, dampness dispelling, tonifying qi, and harmonizing formulas), exhibit shared antioxidative properties and target multiple oxidative stress pathways. However, the time-response, cumulative effects, and safety (hyperkalemia risk) of these sixteen PRCHMDKD on cardiorenal and survival outcomes in patients with overall and advanced DKD remain unresolved. METHODS: This retrospective cohort study analyzed national health insurance claims data in 2000-2017. Four statistical methods, including Cox proportional hazards models, complementary restricted mean survival time (RMST), propensity score matching, and competing risk analysis for end-stage renal disease (ESRD), were employed to investigate this relationship. The study included 43,480 PRCHMDKD users and an equal number of matched nonusers within the overall DKD patient population. For advanced DKD patients, the cohort comprised 1,422 PRCHMDKD users and an equivalent number of matched nonusers. RESULTS: PRCHMDKD use in overall and advanced, respectively, DKD patients was associated with time-dependent reductions in adjusted hazard ratios for ESRD (0.66; 95% CI, 0.61-0.70 vs. 0.81; 0.65-0.99), all-cause mortality (0.48; 0.47-0.49 vs. 0.59; 0.50-0.70), and cardiovascular mortality (0.50; 0.48-0.53 vs. 0.61; 0.45-0.82). Significant differences in RMST were observed in overall and advanced, respectively, DKD patients, favoring PRCHMDKD use: 0.31 years (95% CI, 0.24-0.38) vs. 0.61 years (0.13-1.10) for ESRD, 2.71 years (2.60-2.82) vs. 1.50 years (1.03-1.98) for all-cause mortality, and 1.18 years (1.09-1.28) vs. 0.59 years (0.22-0.95) for cardiovascular mortality. Additionally, hyperkalemia risk did not increase. These findings remained consistent despite multiple sensitivity analyses. Notably, the cumulative effects of utilizing at least four or five classes and multiple botanical drugs from the sixteen PRCHMDKD provided enhanced renoprotection for patients with both overall and advanced DKD. This suggests that there is involvement of multiple targets within the oxidative stress pathways associated with DKD. CONCLUSION: This real-world study suggests that using these sixteen PRCHMDKD provides time-dependent cardiorenal and survival benefits while ensuring safety for DKD patients.
引用
- Chen HT, Tung CH, Yu BH, et al. Sixteen prescribed Chinese herbal medicines provide time-dependent cardiorenal and survival benefits in patients with overall and advanced diabetic kidney disease: a real-world study in Taiwan. Front Pharmacol. 2024. PMID: 39239654. doi:10.3389/fphar.2024.1297854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。